Development and validation of disulfidptosis-related genes signature for patients with glioma

Bibliographic Details
Title: Development and validation of disulfidptosis-related genes signature for patients with glioma
Authors: Jia Wang, Junchi Luo, Sha Yang, Yongbing Deng, Peng Chen, Ying Tan, Yang Liu
Source: Discover Oncology, Vol 15, Iss 1, Pp 1-20 (2024)
Publisher Information: Springer, 2024.
Publication Year: 2024
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Disulfidptosis, Prognosis, Glioma, Tumor immune microenvironment, Drug sensitivity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Background Disulfidptosis has recently emerged as a novel form of regulated cell death (RCD). Evasion of cell death is a hallmark of cancer, and the resistance of many tumors to apoptosis-inducing therapies has heightened interest in exploring alternative RCD mechanisms. Methods Transcriptomic and clinical data were obtained from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Chinese Glioma Genome Atlas (CGGA). Glioma samples were classified using non-negative matrix factorization (NMF). A predictive model was constructed using Lasso regression analysis, and its performance was evaluated through receiver operating characteristic (ROC) and Kaplan–Meier survival analyses. The relationship between the model and the tumor immune microenvironment (TIME) as well as treatment sensitivity was also assessed. Finally, we validated the expression of key signature genes in glioma. Results Glioma samples were categorized into two distinct subtypes based on disulfidptosis-related genes, showing significant differences in overall survival (OS) and progression-free survival (PFS) between the subtypes. A genetic risk score model was then developed using these genes. A nomogram predicting OS was constructed using the risk score and clinical variables. Patients were stratified into low- and high-risk groups based on the median risk score from the TCGA cohort. Low-risk patients had significantly better outcomes compared to high-risk patients (TCGA cohort, OS: p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2730-6011
Relation: https://doaj.org/toc/2730-6011
DOI: 10.1007/s12672-024-01664-z
Access URL: https://doaj.org/article/cd79b1653ecb42d8aedcfadd28f236ae
Accession Number: edsdoj.79b1653ecb42d8aedcfadd28f236ae
Database: Directory of Open Access Journals
More Details
ISSN:27306011
DOI:10.1007/s12672-024-01664-z
Published in:Discover Oncology
Language:English